Yosef Jalal Abadi; Alireza Shirazi; Mohammadreza Ghavam Nasiri; Amir Al Davood; ِDaryoosh Sardari
Volume 22, Special Issue , March and April 2016, , Pages 1139-1157
Abstract
Background & Objectives: One of the major causes of death in the world is cancer.Due to significant advances in molecular and cellular biology, previous approaches in cancer treatment have progressed, applying new strategies.Identification and use of chemotherapy and radiation sensitizers and their ...
Read More
Background & Objectives: One of the major causes of death in the world is cancer.Due to significant advances in molecular and cellular biology, previous approaches in cancer treatment have progressed, applying new strategies.Identification and use of chemotherapy and radiation sensitizers and their effect on the further destruction of the cancer therapy.COX-2 enzyme inhibition with Celecoxib and the prevention of the restoration of this tumour.
Evidence Acquisition:The mechanism by which the cells are radiosensitized can increase the initial damage, inhibiting the restoration and redistribution of the cell cycle as well as blocking in the more radiosensitized zone.Enhanced response to treatment would be initiated by identifying enzymes that are involved in increasing tumour growth and followed by inhibiting tumour growth and restoration. COX-2 is one of the enzymes expressed highly in tumour growth. Inhibiting this enzyme will enhance the response rate of treatment followed by the death of tumour cells.
Results: There are five mechanisms that the COX-2 enzyme applies to develop tumours and increase the malignant phenotype of tumour cells.The drug inhibits the COX-2 enzyme through TNF-α signalling by nuclear transfer inhibition of growth factor.It also inhibits NF-KB transcription factor activation.Apoptosis inhibition is one of the mechanisms implemented by COX-2 that increases tumourigenesis.Cell cycle arrest at G1-S is one of the most sensitized areas to radiation. Studies in the field of pancreatic and ovarian carcinoma cells show cell cycle arrest at G1-S; the mechanism by which this arrest happens is not fully understood.
Conclusions: Celecoxib, as a COX-2 inhibitor that affects and inhibits some enzymes and creates changes in the cell cycle process, has the role of a radiosensitizer.Celecoxib prevents cancer. Celecoxib inhibits tumour growth delay and the amount is insignificant.Concomitant use of Celecoxib with chemotherapy and radiotherapy with a synergy that will further damage the cells during and after radiation therapy.